Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0142 Transporter Info
Gene Name SLC22A16
Transporter Name Fly-like putative transporter 2
Gene ID
85413
UniProt ID
Q86VW1
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Chemical Compound

  DT Modulation1

 Benzo(a)pyrene results in increased methylation of SLC22A16 5' UTR [8]

Regulation Mechanism

 Transcription Factor Info

  2-palmitoylglycerol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 2-palmitoylglycerol results in increased expression of SLC22A16 mRNA [7]

Regulation Mechanism

 Transcription Factor Info

  CGP 52608

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 CGP 52608 promotes the reaction RORA protein binds to SLC22A16 gene [9]

Regulation Mechanism

 Transcription Factor Info

  Daunorubicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Daunorubicin inhibits the reaction SLC22A16 protein results in increased uptake of Doxorubicin [10]

Regulation Mechanism

 Transcription Factor Info

  Dopamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Dopamine inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  Doxorubicin

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Daunorubicin inhibits the reaction SLC22A16 protein results in increased uptake of Doxorubicin [10]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 SLC22A16 protein results in increased uptake of Doxorubicin [10]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation3

 Tetraethylammonium results in decreased activity of SLC22A16 protein which results in decreased susceptibility to Doxorubicin [10]

Regulation Mechanism

 Transcription Factor Info

  entinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 entinostat results in increased expression of SLC22A16 mRNA [5]

Regulation Mechanism

 Transcription Factor Info

  Guanidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Guanidine inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  Hydralazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Hydralazine co-treated with Valproic Acid results in increased expression of SLC22A16 mRNA [11]

Regulation Mechanism

 Transcription Factor Info

  Lidocaine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Lidocaine inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  N(1)-methylnicotinamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 N(1)-methylnicotinamide inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  Procainamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Procainamide inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  S-(1,2-dichlorovinyl)cysteine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 S-(1,2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides results in decreased expression of SLC22A16 mRNA [12]

Regulation Mechanism

 Transcription Factor Info

  Serotonin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Serotonin inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  Tetraethylammonium

            8 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Dopamine inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 Guanidine inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation3

 Lidocaine inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation4

 N(1)-methylnicotinamide inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation5

 Procainamide inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation6

 Serotonin inhibits the reaction SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation7

 SLC22A16 protein results in increased uptake of Tetraethylammonium [10]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation8

 Tetraethylammonium results in decreased activity of SLC22A16 protein which results in decreased susceptibility to Doxorubicin [10]

Regulation Mechanism

 Transcription Factor Info

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Hydralazine co-treated with Valproic Acid results in increased expression of SLC22A16 mRNA [11]

Regulation Mechanism

 Transcription Factor Info

  vanadyl sulfate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 vanadyl sulfate results in increased expression of SLC22A16 mRNA [2]

Regulation Mechanism

 Transcription Factor Info

Approved Drug

  Folic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Folic Acid inhibits the expression of SLC22A16 [1]

Drug in Phase 3 Trial

  Vanadyl sulfate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Vanadyl sulfate increases the expression of SLC22A16 [2]

Drug in Phase 2 Trial

  MS-275

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 MS-275 increases the expression of SLC22A16 [5]

Drug in Preclinical Test

  (+)-JQ1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 (+)-JQ1 inhibits the expression of SLC22A16 [4]

Natural Product

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Tobacco Smoke Pollution inhibits the expression of SLC22A16 [6]

Carcinogen

  Benzo(a)pyrene

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Benzo(a)pyrene inhibits the expression of SLC22A16 [3]
References
1 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92.
2 Discrimination of vanadium from zinc using gene profiling in human bronchial epithelial cells. Environ Health Perspect. 2005 Dec;113(12):1747-54.
3 Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
4 BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012 Oct 4;120(14):2843-52.
5 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
6 Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
7 Direct effect of 2-palmitoyl glycerol on promotion of gamma aminobutyric acid synthesis in normal human fetal-derived astrocytes. FEBS Open Bio. 2023;13(7):1320-1332.
8 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
9 Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
10 Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun. 2005;333(3):754-62.
11 A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006;1(1):e98.
12 The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine inhibits lipopolysaccharide-induced inflammation transcriptomic pathways and cytokine secretion in a macrophage cell model. Toxicol In Vitro. 2022;84:105429.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.